Pipeline
TRN
Candidate & Indication
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
MYC/TF Fusions
KB-0742
(CDK9 Inhibitor)
IRF4
KB-9558
(p300 KAT inhibitor)
R/R Multiple Myeloma
MYC
Undisclosed
β-Catenin
Undisclosed
Undis-closed
Discovery Collaboration
Multiple
Undisclosed
Additional proprietary programs from mapping and screening the MYC, AR, MYB, IRF4 and other TRNs
KAT: lysine acetyltransferase. IRF4: interferon regulatory factor 4. TF: transcription factor. TRN: transcription regulatory network.
We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.